Is Tesamorelin FDA Approved? Yes, As Egrifta

The Short Answer

Yes, tesamorelin Explore PeRxTesamorelinMetabolic Optimization PeptideView peptide is FDA approved. The FDA approved it on November 10, 2010 as Egrifta, a daily injection made by Theratechnologies, and that approval has never been withdrawn. Two later versions of the same drug have been approved since: Egrifta SV in November 2018 and Egrifta WR in March 2025. Among the growth hormone peptides that show up in compounding, tesamorelin is the only one with a current approval. Sermorelin Read nextIs Sermorelin FDA Approved? Yes Until 2008Sermorelin has a unique regulatory history. It was FDA-approved in 1997 as Geref Diagnostic for testing pituitary function, and its therapeutic form (Geref) was used for pediatric growth hormone deficiency. Then the manufacturer discontinued it in 2008. Today Sermorelin is only available as a compounded medication. Here is the full story.Read article lost its brand in 2008, and CJC-1295 and ipamorelin Read nextIs CJC-1295/Ipamorelin FDA Approved? (2026 Answer)The short answer is no. CJC-1295 and Ipamorelin are not FDA-approved drugs. They are compounded medications, prescribed by licensed providers and prepared by regulated pharmacies. Here is what that actually means for you, how it compares to FDA-approved peptides, and why the distinction matters less than most people think.Read article were never approved at all.

That is where most websites stop. The rest matters more if you are the one holding the syringe. The approval is narrow: it covers one condition, excess abdominal fat in adults with HIV-associated lipodystrophy, and nothing else. The prescribing information says in plain words that Egrifta is not indicated for weight loss management. So when a clinic prescribes compounded tesamorelin to someone without HIV who wants to lose visceral fat, that is an off-label prescription of a compounded copy of an approved drug. Legal, common and regulated, but a different thing from "FDA approved for what I am using it for."

What the Approval Actually Covers

The current Egrifta WR label, revised in March 2025, describes the drug as a growth hormone-releasing factor analog indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. Lipodystrophy here means the abnormal fat redistribution that developed in many people on older antiretroviral regimens: fat lost from the face and limbs, fat gained deep in the abdomen around the organs. That deep fat, visceral adipose tissue or VAT, is the target of the drug.

The label then lists three limitations of use. First, the long-term cardiovascular safety of the drug has not been established, and prescribers are told to reconsider continuing it in patients whose visceral fat has not come down. Second, the drug is not indicated for weight loss management because it has a weight-neutral effect. Third, there is no evidence it improves adherence to antiretroviral therapy. That middle limitation should reframe expectations for anyone who has read about tesamorelin as a fat-loss peptide: in the pivotal trials the scale barely moved even as the CT scans did.

EGRIFTA WR (tesamorelin) for injection, Full Prescribing Information, Theratechnologies, revised March 2025. Indications and Usage, Limitations of Use, Contraindications, Warnings and Precautions. View study

Three Formulations, One Approval

Egrifta has been reformulated twice, which is why three names appear on pharmacy paperwork. All three sit under one FDA application, number 022505, which was deemed a Biologics License Application on March 23, 2020 when the FDA moved larger peptides into the biologics framework.

The Evidence Behind the Approval

The approval rested on two Phase 3 trials with the same design, run in HIV-infected adults on antiretroviral therapy who had accumulated abdominal fat. The first, published in the New England Journal of Medicine in 2007, randomized 412 patients to 2 mg of tesamorelin or placebo injected daily for 26 weeks. Visceral fat measured by CT fell 15.2% on tesamorelin and rose 5.0% on placebo. Triglycerides dropped 50 mg/dL versus a 9 mg/dL rise on placebo. IGF-1, the growth factor the liver makes more of when GH rises, increased 81%. Adverse events were similar between groups overall, though more tesamorelin patients withdrew because of one.

Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. View study

The pooled analysis of both trials, 806 patients in total, put the treatment effect on visceral fat at -15.4% at 26 weeks with no meaningful change in the subcutaneous fat under the skin. Patients who stayed on the drug for a full year held a 17.5% reduction. Body image, triglycerides and the cholesterol-to-HDL ratio improved, and glucose measures did not differ meaningfully from placebo at 26 or 52 weeks. The extension study made one more point every patient should hear before starting: when tesamorelin was stopped, the visceral fat came back. The effect lasts as long as the treatment does.

Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-4304. View study

Falutz J, Allas S, Mamputu JC, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22(14):1719-1728. View study

What the Label Says About Safety

Because Egrifta went through full FDA review, its label carries quantified safety data that no other compounded GH peptide can offer. The most common adverse reactions, reported by more than 5% of patients, were joint pain, injection site redness and itching, pain in an extremity, swelling of the legs and feet, and muscle pain. Injection site reactions occurred in 25% of treated patients versus 14% on placebo during the first 26 weeks. Hypersensitivity reactions, including rash, hives and flushing, occurred in 4%.

Two warnings deserve more attention than clinic marketing gives them. Among patients on the drug for 26 weeks, 47% had IGF-1 more than two standard deviations above normal and 36% more than three; the label asks prescribers to monitor IGF-1 and consider stopping when it stays high, because the long-term effects of elevated IGF-1 are unknown. And 5% of treated patients versus 1% on placebo reached an HbA1c of 6.5% or higher by week 26, a diabetes-range reading, with an odds ratio of 3.3. Tesamorelin is contraindicated in active malignancy, in pregnancy, in anyone with a disrupted hypothalamic-pituitary axis from surgery, tumor or head trauma, and in anyone with a known hypersensitivity to it. These are not concerns pulled from animal data; they are what happened to patients in the trials that earned the approval.

Later Trials Extended the Picture

Two later NIH-funded trials, both still in people with HIV, looked at the liver. A 2014 JAMA study of 48 patients found tesamorelin reduced visceral fat by a net 42 cm2 and modestly reduced liver fat over six months. A 2019 Lancet HIV trial in 61 people with HIV and fatty liver found a 37% relative reduction in liver fat after a year, with 35% of tesamorelin patients reaching a liver fat fraction under 5% versus 4% on placebo, and no difference in glucose or HbA1c. The authors wrote that tesamorelin "might be beneficial" and called for longer studies with biopsies. Neither result has been added to the approved indication.

Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. View study

Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830. View study

What "Approved" Does Not Mean

If you do not have HIV-associated lipodystrophy, no FDA approval covers your use of tesamorelin. That is not a technicality. The FDA approves a drug for a specific indication in a specific population, and the findings above were generated in that population: adults with HIV, most of them men, most on antiretroviral regimens that alter metabolism on their own. Whether the same 15% visceral fat reduction shows up in a 48-year-old without HIV is a reasonable hypothesis, not an established fact, and the label does not claim it.

Data outside HIV exist, but they are small. A 12-month placebo-controlled trial at Massachusetts General Hospital enrolled 39 obese adults with reduced growth hormone secretion and found that the IGF-1 rise on tesamorelin tracked with faster phosphocreatine recovery in muscle, a marker of mitochondrial function. A separate 20-week trial of 152 older adults, some with mild cognitive impairment, reported a favorable effect of the GHRH analog on executive function alongside a 7.4% drop in body fat; mostly mild adverse events were reported by 68% of treated adults versus 36% on placebo. Both are real randomized trials. Neither is large enough, long enough or replicated enough to support an indication, and the cognition finding has not been confirmed in a larger study. Read them as reasons the research continues, not as promises.

Makimura H, Murphy CA, Feldpausch MN, Grinspoon SK. The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH. J Clin Endocrinol Metab. 2014;99(1):338-343. View study

Baker LD, Barsness SM, Borson S, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429. View study

Stanley TL, Falutz J, Marsolais C, et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. 2012;54(11):1642-1651. View study

Compounded Tesamorelin and the Law

Almost nobody outside an HIV clinic receives Egrifta. The tesamorelin people encounter through telehealth is compounded: a state-licensed 503A pharmacy prepares it from bulk tesamorelin powder for an individual prescription. Two separate legal questions decide whether that is allowed, and tesamorelin answers them differently from every other GH peptide.

Why Tesamorelin Never Needed a Bulks-List Review

Section 503A of the Federal Food, Drug, and Cosmetic Act lets a compounding pharmacy use a bulk drug substance only if it passes through one of three doors: the substance complies with a United States Pharmacopeia or National Formulary monograph; or, if no monograph exists, it is a component of a drug the FDA has approved; or, failing both, it appears on the 503A bulks list the FDA develops through rulemaking. Tesamorelin walks through the second door. It is the active ingredient of Egrifta, an approved drug, so a pharmacy can compound it without asking the FDA to add it to any list.

21 U.S.C. 353a (Section 503A of the Federal Food, Drug, and Cosmetic Act), subsections (b)(1)(A)(i) and (b)(2). Legal Information Institute, Cornell Law School. View study

That third door is where the peptide news of the past three years has happened. Substances that need the bulks list get sorted into categories while the FDA evaluates them, and in September 2023 the agency moved a group of peptides, including BPC-157 Explore PeRxBPC-157The Body Protection CompoundView peptide , CJC-1295, ipamorelin, MOTS-c Explore PeRxMOTS-cThe Mitochondrial PeptideView peptide , epitalon Explore PeRxEpitalonThe Longevity PeptideView peptide and thymosin alpha-1 Explore PeRxThymosin Alpha-1Immune System OptimizerView peptide , into Category 2, the bucket for substances it believes may present significant safety risks. The FDA removed peptides from Category 2 in April 2026 and sent several to its Pharmacy Compounding Advisory Committee for votes. Tesamorelin appears nowhere in that story: it is not on the Category 2 page, it was never nominated for the bulks list, and no committee has voted on it, because it never needed to be there. We checked the FDA lists directly on September 28, 2026; some secondary sources wrongly call tesamorelin a Category 2 substance.

FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2 list), and Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. Accessed September 28, 2026. View study

The "Essentially a Copy" Rule

Passing the bulks question opens a second one that only applies to drugs like tesamorelin. Section 503A also says a pharmacy may not compound "regularly or in inordinate amounts" a drug product that is essentially a copy of a commercially available drug. Congress wrote that rule so compounding could not become a way to mass-produce cheaper versions of approved medicines. Egrifta is commercially available, so a compounded vial of tesamorelin has to be something other than a copy of it.

The statute defines the exception. A compounded drug is not essentially a copy when there is a change, made for an identified individual patient, that produces for that patient a significant difference, as determined by the prescribing practitioner, between the compounded drug and the commercially available product. The FDA guidance on this rule, finalized in January 2018, adds the practical requirement: the prescriber should document that determination on the prescription, and if the prescription is silent the pharmacy is expected to call the prescriber and record the answer with the date. The FDA says it generally does not intend to second-guess a documented determination, but it does intend to check that one was made.

FDA. Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry. January 2018. View study

What does a significant difference look like with tesamorelin? The compounded product PeRx dispenses is a ready-to-use solution at 3 mg/mL in a multi-dose vial, dosed at 2 mg daily. Egrifta WR is an 11.6 mg powder in a single-patient vial mixed with diluent once a week and injected at 1.28 mg daily; Egrifta SV is a 2 mg powder vial mixed each day. Different strength, different dosage form, different dose, and no mixing step for a patient who cannot manage one. Whether those differences are significant for a particular patient is the prescribing physician's call to make and document, one prescription at a time. It is a pathway Congress wrote into the law, not a loophole, and it is also the part of a compounded tesamorelin prescription that regulators look at first. As of September 2026 the FDA has issued no guidance specific to compounded tesamorelin, so treat the status as settled in the statute and unsettled in enforcement priorities, like most of compounding.

What PeRx Prescribes

PeRx does not sell Egrifta. A licensed provider reviews your intake and, if tesamorelin is appropriate, prescribes compounded tesamorelin from a state-licensed 503A pharmacy at 2 mg subcutaneously once daily, the dose the Phase 3 trials used. The vial ships fully reconstituted and ready to use, refrigerated, at $229 per month, with third-party purity testing available on request. The screening mirrors the contraindications on the Egrifta label: an active or recent cancer, pregnancy or breastfeeding, and any history of pituitary surgery, tumor or head trauma are reasons the provider will decline. Blood glucose and IGF-1 are the two labs the trial data argue for, and the provider decides at prescription time whether and when you need them.

For the full clinical picture, the tesamorelin guide Read nextTesamorelin Peptide: Benefits, Dosage & Visceral FatMost peptides in the compounding space have animal studies and early clinical signals. Tesamorelin has two Phase 3 randomized controlled trials, 816 patients, CT-measured visceral fat data, and an FDA approval. It is a synthetic analog of growth hormone-releasing hormone that triggers your pituitary to produce its own GH in a natural, pulsatile pattern. The result: targeted visceral fat loss without the side effects of injecting growth hormone directly.Read article covers mechanism and expectations, the tesamorelin dosage chart Read nextTesamorelin Dosage Chart: Units, Timing, CostTesamorelin dosing numbers found online disagree with each other for a reason: three different Egrifta labels say 2 mg, 1.4 mg, and 1.28 mg, and none of them describe a compounded vial. This page sorts out the three labels, converts milligrams to insulin-syringe units at the 3 mg/mL concentration PeRx ships, and covers timing, cycle length, missed doses, and what a month costs, as of August 31, 2026.Read article walks through units and timing, tesamorelin results Read nextTesamorelin Results: What the Trials Actually ShowedSearch for results on almost any peptide and you get mouse studies and marketing. Tesamorelin is the exception. The molecule went through two Phase 3 randomized trials with more than 800 patients, and the endpoint was not a survey or a scale. It was visceral fat measured by CT scan. This article walks through those numbers, the population they came from, what a realistic timeline looks like, and why the honest version of "tesamorelin before and after" involves a tape measure instead of a mirror.Read article sets a realistic timeline, and where to inject tesamorelin Read nextWhere to Inject Tesamorelin: Sites and RotationTesamorelin is the rare peptide with FDA-approved labeling that tells you exactly where it goes: a subcutaneous injection into the abdomen, rotated. As of July 2026, that approved route is the anchor for how patients use it. Here is the practical site map, the rotation habit that keeps absorption consistent, and the technique details patients ask about after their first vial arrives.Read article covers the abdomen-only technique the label calls for. Because the effect reverses when you stop, the peptide cycling guide Read nextPeptide Cycling Chart: When to Pause Each ClassPeptide therapy is rarely meant to run forever. Some peptides need scheduled breaks to keep working. Others can be used continuously. The right cycle depends on the peptide class, your goals, and what is happening at the receptor level. Here is the practical guide to cycling, peptide by peptide.Read article is worth reading before you start rather than after.

Tesamorelin vs Other GH Peptides: Regulatory Comparison

Tesamorelin, sermorelin Read nextTesamorelin vs Sermorelin: Which One Fits Your Goal?Tesamorelin and sermorelin press the same button on the pituitary, so most comparison pages end up ranking them by strength. That misses the point. One has two Phase 3 trials with CT scans behind a single, narrow result. The other has more than three decades of clinical history and a thin adult evidence file. PeRx prescribes both at the same price, which leaves the only question that matters: what are you actually trying to change?Read article and CJC-1295 with ipamorelin Read nextTesamorelin vs CJC-1295/Ipamorelin 2026: FDA vs DualTesamorelin is the only FDA-approved growth hormone peptide. CJC-1295/Ipamorelin is the most popular compounded GH stack. Both stimulate your pituitary to produce growth hormone, but they do it differently and they have very different regulatory histories. Here is the honest comparison to help you choose.Read article all raise growth hormone by acting on the pituitary, and clinics often present them as interchangeable menu items. Their legal footing is not interchangeable at all.

Tesamorelin carries the strongest evidence and the clearest bulks-list footing, plus an extra copy-rule test because a brand exists. Sermorelin Explore PeRxSermorelinThe Growth Hormone OptimizerView peptide has the cleanest compounding logic because nothing on the market competes with it. CJC-1295 and ipamorelin have the most clinic marketing and the shakiest regulatory ground. The FDA-approved peptides guide Read nextFDA-Approved Peptides: The Full List (2026)Peptide drugs have been FDA-approved for over forty years, from recombinant insulin in 1982 to tirzepatide in 2022. Most of the peptides people actually search for, though, are not on that list. This guide lays out every FDA-approved peptide drug with its brand names and approval year, explains the difference between an approved drug, a compounded medication, and a research chemical, and covers where the 2026 FDA compounding review left peptides like BPC-157. Current as of August 2026.Read article runs the same analysis for BPC-157, PT-141 Explore PeRxPT-141On-Demand Intimacy EnhancementView peptide and the GLP-1s. Which one belongs in your protocol is a clinical question; which one is FDA approved is a factual one, and only tesamorelin answers yes.

Is Tesamorelin FDA Approved? Common Questions